Epithelial-mesenchymal transition (EMT) and regulation of EMT factors by steroid nuclear receptors in breast cancer: A review and in silico investigation

Journal of Clinical Medicine

Volumn 5, Issue 1, 2016, Pages

  Voutsadakis, Ioannis A ^a,b  

^a Sault Area Hospitals   (Canada)

^b NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

AR; Breast cancer; Epithelial mesenchymal transition; ER ; ER ; GR; Mesenchymal epithelial transition; MR; PR; Steroid nuclear receptors

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CASEIN; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; GOOSECOID PROTEIN; INHIBITOR OF DIFFERENTIATION PROTEIN; LADYBIRD HOMEOBOX 1 PROTEIN; MICRORNA 200; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PIONEER FACTOR; PROGESTERONE; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; STEROID NUCLEAR RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; WNT4 PROTEIN;

BINDING SITE; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; COMPUTER MODEL; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HUMAN; META ANALYSIS (TOPIC); METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION;

EID: 85048775182     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5010011     Document Type: Review

References (142)

1. Le Du, F.; Eckhardt, B.L.; Lim, B.; Litton, J.K.; Moulder, S.; Meric-Bernstam, F.; Gonzalez-Angulo, A.M.; Ueno, N.T. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015, 6, 12890–12908. [PubMed]
2. Voutsadakis, I.A. Peroxisome proliferator activated receptor-a and the ubiquitin-proteasome system in colorectal cancer. World J. Gastrointest. Oncol. 2010, 2, 235–241. [CrossRef] [PubMed]
3. Anbalagan, M.; Huderson, B.; Murphy, L.; Rowan, B.G. Post-translational modifications of nuclear receptors and human disease. Nuclear Recept. Signal. 2012, 10, e001.
4. Helsen, C.; Claessens, F. Looking at nuclear receptors from a new ankle. Mol. Cell. Endocrinol. 2014, 382, 97–106. [CrossRef] [PubMed]
5. Beato, M.; Vicent, G.P. Impact of chromatin structure and dynamics on PR signaling. The initial steps in hormonal gene regulation. Mol. Cell. Endocrinol. 2012, 357, 37–42. [CrossRef] [PubMed]
6. Grøntved, L.; Hager, G.L. Impact of chromatin structure on PR signaling: Transition from local to global analysis. Mol. Cell. Endocrinol. 2012, 357, 30–36. [CrossRef] [PubMed]
7. Burd, C.J.; Archer, T.K. Chromatin architecture defines the glucocorticoid response. Mol. Cell. Endocrinol. 2013, 380, 25–31. [CrossRef] [PubMed]
8. Voutsadakis, I.A. The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J. Biomed. Sci. 2012, 19, 67. [CrossRef] [PubMed]
9. Voutsadakis, I.A. Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial masenchymal transition of cancer. Tumour Biol. 2012, 33, 897–910. [CrossRef] [PubMed]
10. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Investig. 2009, 119, 1429–1437. [CrossRef] [PubMed]
11. Micalizzi, D.S.; Farabaugh, S.M.; Ford, H.L. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 2010, 15, 117–134. [CrossRef] [PubMed]
12. Guo, F.; Parker Kerrigan, B.C.; Yang, D.; Hu, L.; Shmulevich, L.; Sood, A.K.; Xue, F.; Zhang, W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J. Hematol. Oncol. 2014, 7, 19. [CrossRef] [PubMed]
13. Voutsadakis, I.A. The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer 2015, 7, 303–319. [CrossRef] [PubMed]
14. Moreno-Bueno, G.; Cubillo, E.; Sarrió, D.; Peinado, H.; Rodríguez-Pinilla, S.M.; Villa, S.; Bolós, V.; Jordá, M.; Fabra, A.; Portillo, F., et al. Genetic profiling of epithelial cells expressing E-Cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in Epithelial-Mesenchymal Transition. Cancer Res. 2006, 66, 9543–9556. [CrossRef] [PubMed]
15. Tran, D.D.; Corsa, C.A.S.; Biswas, H.; Aft, R.L. Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during Epithelial-Mesenchymal Transition predicts for human breast cancer recurrence. Mol. Cancer Res. 2011, 9, 1644–1657. [CrossRef] [PubMed]
16. De Herreros, A.G.; Peiró, S.; Nassour, M.; Savagner, P. Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J. Mammary Gland Biol. Neoplasia 2010, 15, 135–147. [CrossRef] [PubMed]
17. Proia, T.A.; Keller, P.J.; Gupta, P.B.; Klebba, I.; Jones, A.D.; Sedic, M.; Gilmore, H.; Tung, N.; Naber, S.P.; Schnitt, S., et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8, 149–163. [CrossRef] [PubMed]
18. Mitre-Aguilar, I.B.; Cabrera-Quintero, A.J.; Zentella-Dehesa, A. Genomic and non-genomic effects of glucocorticoids: Implications for breast cancer. Int. J. Clin. Exp. Pathol. 2015, 8, 1–10. [PubMed]
19. Denayer, S.; Helsen, C.; Thorrez, L.; Haelens, A.; Claessens, F. The rules of DNA recognition by the Androgen Receptor. Mol. Endocrinol. 2010, 24, 898–913. [CrossRef] [PubMed]
20. Zhao, C.; Dahlman-Wright, K.; Gustafsson, J.-Å. Estrogen signalling via Estrogen Receptor. J. Biol. Chem. 2010, 285, 39575–39579. [CrossRef] [PubMed]
21. Ratman, D.; Vande Berghe, W.; Dejager, L.; Libert, C.; Tavernier, J.; Beck, I.M.; de Bosscher, K. How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering. Mol. Cell. Endocrinol. 2013, 380, 41–54. [CrossRef] [PubMed]
22. Lupien, M.; Brown, M. Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer 2009, 16, 381–389. [CrossRef] [PubMed]
23. Horwitz, K.B.; Dye, W.W.; Chuck Harrell, J.; Kabos, P.; Sartorius, C.A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci. USA 2008, 105, 5774–5779. [CrossRef] [PubMed]
24. Kabos, P.; Haughian, J.M.; Wang, X.; Dye, W.W.; Finlayson, C.; Elias, A.; Horwitz, K.B.; Sartorius, C.A. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res. Treat. 2011, 128, 45–55. [CrossRef] [PubMed]
25. Harrison, H.; Simões, B.M.; Rogerson, L.; Howell, S.J.; Landberg, G.; Clarke, R.B. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res. 2013, 15, R21. [CrossRef] [PubMed]
26. Hong, S.H.; Nah, H.Y.; Lee, Y.J.; Lee, J.W.; Park, J.H.; Kim, S.J.; Lee, J.B.; Yoon, H.S.; Kim, C.H. Expression of Estrogen Receptor-a and –b, Glucocorticoid Receptor, and Progesterone Receptor genes in human embryonic stem cells and embryoid bodies. Mol. Cells 2005, 18, 320–325.
27. Guttilla, I.K.; Adams, B.D.; White, B.A. ERa, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol. Metable 2012, 23, 73–82. [CrossRef] [PubMed]
28. Al Saleh, S.; Al Mulla, F.; Luqmani, Y.A. Estrogen Receptor silencing induces Epithelial to Mesenchymal Transition in human breast cancer cells. PLoS ONE 2011, 6, e20610. [CrossRef] [PubMed]
29. Bouris, P.; Skandalis, S.S.; Piperigkou, Z.; Afratis, N.; Karamanou, K.; Aletras, A.J.; Moustakas, A.; Theocharis, A.D.; Karamanos, N.K. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015, 43, 42–60. [CrossRef] [PubMed]
30. Ito, I.; Hanyu, A.; Wayama, M.; Goto, N.; Katsuno, Y.; Kawasaki, S.; Nakajima, Y.; Kajiro, M.; Komatsu, Y.; Fujimura, A., et al. Estrogen inhibits Transforming Growth Factor signalling by promoting Smad2/3 degradation. J. Biol. Chem. 2010, 285, 14747–14755. [CrossRef] [PubMed]
31. Grimm, S.L.; Rosen, J.M. Stop! In the name of transforming growth factor-b; keeping estrogen receptor-a-positive mammary epithelial cells from proliferating. Breast Cancer Res. 2006, 8, 106. [CrossRef] [PubMed]
32. Wang, X.; Belguise, K.; Kersual, N.; Kirsch, K.H.; Mineva, N.D.; Galtier, F.; Chalbos, D.; Sonenshein, G.E. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 2007, 9, 470–478. [CrossRef] [PubMed]
33. Wang, X.; Belguise, K.; O’Neill, C.F.; Sánchez-Morgan, N.; Romagnoli, M.; Eddy, S.F.; Mineva, N.D.; Yu, Z.; Min, C.; Trinkaus-Randall, V., et al. RelB NF-kB represses Estrogen Receptor a expression via induction of the zinc finger protein Blimp1. Mol. Cell. Biol. 2009, 29, 3832–3844. [CrossRef] [PubMed]
34. Guo, S.; Li, Y.; Tong, Q.; Gu, F.; Zhu, T.; Fu, L.; Yang, S. dEF1 down-regulates ER-a expression and confers tamoxifen resistance in breast cancer. PLoS ONE 2012, 7, e52380. [CrossRef] [PubMed]
35. Scherbakov, A.M.; Andreeva, O.E.; Shatskaya, V.A.; Krasil’nikov, M.A. The relationships between Snail1 and estrogen receptor signalling in breast cancer cells. J. Cell. Biochem. 2012, 113, 2147–2155. [CrossRef] [PubMed]
36. Mishra, S.K.; Talukder, A.H.; Gururaj, A.E.; Yang, Z.; Singh, R.R.; Mahoney, M.G.; Franci, C.; Vadlamudi, R.K.; Kumar, R. Upstream determinants of Estrogen Receptor-a regulation of Metastatic Tumor Antigen 3 pathway. J. Biol. Chem. 2004, 279, 32709–32715. [CrossRef] [PubMed]
37. Haldosén, L.-A.; Zhao, C.; Dahlman-Wright, K. Estrogen receptor beta in breast cancer. Mol. Cell. Endocrinol. 2014, 382, 665–672. [CrossRef] [PubMed]
38. Speirs, V.; Skliris, G.P.; Burdall, S.E.; Carder, P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J. Clin. Pathol. 2002, 55, 371–374. [CrossRef] [PubMed]
39. Fox, E.M.; Davis, R.J.; Shupnik, M.A. ERb in breast cancer- Onlooker, passive player, or active protector? Steroids 2008, 73, 1039–1051. [CrossRef] [PubMed]
40. Guo, L.; Meng, J.; Yilamu, D.; Jakulin, A.; Fu, M.; Wang, B.; Abulajiang, G. Significance of ERb expression in different molecular subtypes of breast cancer. Diagn. Pathol. 2014, 9, 20. [CrossRef] [PubMed]
41. Reese, J.M.; Suman, V.J.; Subramaniam, M.; Wu, X.; Negron, V.; Gingery, A.; Pitel, K.S.; Shah, S.S.; Cunliffe, H.E.; McCullough, A.E., et al. ERb1: Characterization, prognosis, and evaluation of treatment strategies in ERa-positive and -negative cancer. BMC Cancer 2014, 14, 749. [CrossRef] [PubMed]
42. Chang, E.C.; Frasor, J.; Komm, B.; Katzenellenbogen, B.S. Impact of Estrogen Receptor b on gene networks regulated by Estrogen Receptor in breast cancer cells. Endocrinology 2006, 147, 4831–4842. [CrossRef] [PubMed]
43. Williams, C.; Edvardsson, K.; Lewandowski, S.A.; Ström, A.; Gustafsson, J.-Å. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008, 27, 1019–1032. [CrossRef] [PubMed]
44. Hefti, M.M.; Hu, R.; Knoblauch, N.W.; Collins, L.C.; Haibe-Kains, B.; Tamimi, R.M.; Beck, A.H. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013, 15, R68. [CrossRef] [PubMed]
45. Chlebowski, R.T.; Anderson, G.L.; Gass, M.; Lane, D.S.; Aragaki, A.K.; Kuller, L.H.; Manson, J.E.; Stefanick, M.L.; Ockene, J.; Sarto, G.E., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304, 1684–1692. [CrossRef] [PubMed]
46. Cancello, G.; Maisonneuve, P.; Rotmensz, N.; Viale, G.; Mastropasqua, M.G.; Pruneri, G.; Montagna, E.; Iorfida, M.; Mazza, M.; Balduzzi, A., et al. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann. Oncol. 2013, 24, 661–668. [CrossRef] [PubMed]
47. Diep, C.H.; Daniel, A.R.; Mauro, L.J.; Knutson, T.P.; Lange, C.A. Progesterone action in breast, uterine, and ovarian cancers. J. Mol. Endocrinol. 2015, 54, R31–R53.[CrossRef] [PubMed]
48. Chen, C.-C.; Hardy, D.B.; Mendelson, C.R. Progesterone Receptor inhibits proliferation of human breast cancer cells via induction of MAPK Phosphatase 1 (MKP-1/DUSP1). J. Biol. Chem. 2011, 286, 43091–43102. [CrossRef] [PubMed]
49. Knutson, T.P.; Lange, C.A. Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol. Ther. 2014, 142, 114–125. [CrossRef] [PubMed]
50. Nguyen, D.H.; Parlow, A.F.; Neville, M.C. Hormonal regulation of tight junction closure in the mouse mammary epithelium during the transition from pregnancy to lactation. J. Endocrinol. 2001, 170, 347–356. [CrossRef]
51. Obr, A.E.; Edwards, D.P. The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol. Cell. Endocrinol. 2012, 357, 4–17. [CrossRef] [PubMed]
52. Brisken, C.; Heineman, A.; Chavarria, T.; Elenbaas, B.; Tan, J.; Dey, S.K.; McMahon, J.A.; McMahon, A.P.; Weinberg, R.A. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000, 14, 650–654. [PubMed]
53. Fernandez-Valdivia, R.; Mukherjee, A.; Creighton, C.J.; Buser, A.C.; DeMayo, F.J.; Edwards, D.P.; Lydon, J.P. Transcriptional response of the murine mammary gland to acute progesterone exposure. Endocrinology 2008, 149, 6236–6250. [CrossRef] [PubMed]
54. Fernandez-Valdivia, R.; Mukherjee, A.; Ying, Y.; Li, J.; Paquet, M.; DeMayo, F.J.; Lydon, J.P. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 2009, 328, 127–139. [CrossRef] [PubMed]
55. Kariagina, A.; Xie, J.; Langohr, I.M.; Opreanu, R.C.; Basson, M.D.; Haslam, S.Z. Progesterone decreases levels of the adhesion protein E-cadherin and promotes invasiveness of steroid receptor positive breast cancers. Horm. Cancer 2013, 4, 381–390.
56. Conneely, O.M.; Mulac-Jericevic, B.; Lydon, J.P. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 2003, 68, 771–778. [CrossRef]
57. Pistelli, M.; Caramanti, M.; Biscotti, T.; Santinelli, A.; Pagliacci, A.; de Lisa, M.; Ballatore, Z.; Ridolfi, F.; Maccaroni, E.; Bracci, R., et al. Androgen Receptor expression in early triple-negative breast cancer: Clinical significance and prognostic associations. Cancers 2014, 6, 1351–1362. [CrossRef] [PubMed]
58. Tsutsumi, Y. Apocrine carcinoma as triple-negative breast cancer: Novel definition of apocrine-type carcinoma as Estrogen/Progesterone Receptor-negative and Androgen Receptor-positive invasive ductal carcinoma. Jpn. J. Clin. Oncol. 2012, 42, 375–386. [CrossRef] [PubMed]
59. Park, S.; Koo, J.; Park, H.S.; Kim, J.H.; Choi, S.Y.; Lee, J.H.; Park, B.W.; Lee, K.S. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 2010, 21, 488–492. [CrossRef] [PubMed]
60. Vera-Badillo, F.E.; Templeton, A.J.; de Gouveia, P.; Diaz-Padilla, I.; Bedard, P.L.; Al-Mubarak, M.; Seruga, B.; Tannock, I.F.; Ocana, A.; Amir, E. Androgen Receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106, 1–11. [CrossRef] [PubMed]
61. Liu, Y.-N.; Lee, H.-J.; Hsu, Y.-H.; Chen, J.-H. Activated Androgen Receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol. Cell. Biol. 2008, 28, 7096–7108. [CrossRef] [PubMed]
62. Voutsadakis, I.A.; Papandreou, C.N. The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol. Oncol. 2012, 30, 752–761. [CrossRef] [PubMed]
63. Hundertmark, S.; Buhler, H.; Rudolf, M.; Weitzel, H.K.; Ragosch, V. Inhibition of 11 beta-hydroxysteroid gehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75–1 breast cancer cells. J. Endocrinol. 1997, 155, 171–180. [CrossRef] [PubMed]
64. Aziz, M.H.; Shen, H.; Maki, C.G. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase C". J. Biol. Chem. 2012, 287, 29825–29836. [CrossRef] [PubMed]
65. Abduljabbar, R.; Negm, O.H.; Lai, C.F.; Jerjees, D.A.; Al-Kaabi, M.; Hamed, M.R.; Tighe, P.J.; Buluwela, L.; Mukherjee, A.; Green, A.R., et al. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Res. Treat. 2015, 150, 335–346. [CrossRef] [PubMed]
66. Buxant, F.; Engohan-Aloghe, C.; Noël, J.-C. Estrogen Receptor, Progesterone Receptor, and Glucoccorticoid Receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl. Immunohistochem. Mol. Morphol. 2010, 18, 254–257. [CrossRef] [PubMed]
67. Vilasco, M.; Communal, L.; Mourra, N.; Courtin, A.; Forgez, P.; Gompel, A. Glucocorticoid receptor and breast cancer. Breast Cancer Res. Treat. 2011, 130, 1–10. [CrossRef] [PubMed]
68. Karmakar, S.; Jin, Y.; Nagaich, A.K. Interaction of Glucoccorticoid Receptor (GR) with Estrogen Receptor (ER) a and Activator Protein 1 (AP1) in dexamethasone-mediated interference of ERa activity. J. Biol. Chem. 2013, 288, 24020–24034. [CrossRef] [PubMed]
69. Bolt, M.J.; Stossi, F.; Newberg, J.Y.; Orjalo, A.; Johansson, H.E.; Mancini, M.A. Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res. 2013, 41, 4036–4048. [CrossRef] [PubMed]
70. Miranda, T.B.; Voss, T.C.; Sung, M.-H.; Baek, S.; John, S.; Hawkins, M.; Grøntved, L.; Schiltz, R.L.; Hager, G.L. Reprogramming the chromatin landscape: Interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 2013, 73, 5130–5139. [CrossRef] [PubMed]
71. Vilasco, M.; Communal, L.; Hugon-Rodin, J.; Penault-Llorca, F.; Mourra, N.; Wu, Z.; Forgez, P.; Gompel, A.; BRACAPS. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res. Treat. 2013, 142, 283–296. [CrossRef] [PubMed]
72. Bai, F.; Chan, H.L.; Scott, A.; Smith, M.D.; Fan, C.; Herschkowitz, J.I.; Perou, C.M.; Livingstone, A.S.; Robbins, D.J.; Capobianco, A.J., et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Res. 2014, 74, 6161–6172. [CrossRef] [PubMed]
73. Lindeman, G.L.; Visvader, J.E. Cell fate takes a slug in BRCA1-associated breast cancer. Breast Cancer Res. 2011, 13, 306. [CrossRef] [PubMed]
74. Pan, D.; Kocherginsky, M.; Conzen, S.D. Activation of the Glucocorticoid Receptor is associated with poor prognosis in Estrogen Receptor-negative breast cancer. Cancer Res. 2011, 71, 6360–6370. [CrossRef] [PubMed]
75. Wyszomierski, S.L.; Rosen, J.M. Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/ Enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. Mol. Endocrinol. 2001, 15, 228–240. [PubMed]
76. Leo, J.C.L.; Guo, C.; Woon, C.T.; Aw, S.E.; Lin, V.C.L. Glucocorticoid and Mineralocorticoid cross-talk with Progesterone Receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 2004, 145, 1314–1321. [CrossRef] [PubMed]
77. Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750–2767. [CrossRef] [PubMed]
78. Skor, M.N.; Wonder, E.L.; Kocherginsky, M.; Goyal, A.; Hall, B.A.; Cai, Y.; Conzen, S.D. Glucocorticoid Receptor antagonism as a novel therapy for triple-negative breast cancer. Clin. Cancer Res. 2013, 19, 6163–6172. [CrossRef] [PubMed]
79. García de Herreros, A.; Baulida, J. Cooperation, amplification, and feed-back in epithelial-mesenchymal transition. Biochim. Biophys. Acta 2012, 1825, 223–228.
80. Kingsley-Kallesen, M.; Mukhopadhyay, S.S.; Wyszomierski, S.L.; Schanler, S.; Schutz, G.; Rosen, J.M. The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol. Endocrinol. 2002, 16, 2008–2018. [CrossRef] [PubMed]
81. Diah, S.; Zhang, G.-X.; Nagai, Y.; Zhang, W.; Gang, L.; Kimura, S.; Abdul Hamid, M.R.W.; Tamiya, T.; Nishiyama, A.; Hitomi, H. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp. Cell Res. 2008, 314, 3654–3662. [CrossRef] [PubMed]
82. Zhang, A.; Jia, Z.; Guo, X.; Yang, T. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am. J. Physiol. Renal Physiol. 2007, 293, F723–F731. [CrossRef] [PubMed]
83. Foubert, E.; De Craene, B.; Berx, G. Key signaling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 2010, 12, 206. [CrossRef] [PubMed]
84. Lee, K.A.; Gjorevski, N.; Boghaert, E.; Radisky, D.C.; Nelson, C.M. Snail1, Snail2, and E47 promote mammary epithelial branching morphogenesis. EMBO J. 2011, 30, 2662–2674. [CrossRef] [PubMed]
85. Gras, B.; Jacqueroud, L.; Wierinckx, A.; Lamblot, C.; Fauvet, F.; Lachuer, J.; Puisieux, A.; Ansieau, S. Snail family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammary epithelial cells. PLoS ONE 2014, 9, e92254. [CrossRef] [PubMed]
86. Zhang, A.; Wang, Q.; Han, Z.; Hu, W.; Xi, L.; Gao, Q.; Wang, S.; Zhou, J.; Xu, G.; Meng, L., et al. Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase. Oncol. Lett. 2013, 6, 339–346. [PubMed]
87. Okubo, T.; Truong, T.K.; Yu, B.; Itoh, T.; Zhao, J.; Grube, B.; Zhou, D.; Chen, S. Down-regulation of promoter I.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, Snail (SnaH). Cancer Res. 2001, 61, 1338–1346. [PubMed]
88. Martin, T.A.; Goyal, A.; Watkins, G.; Jiang, W.G. Expression of the transcription factor Snail, Slug, and Twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 2005, 12, 1–9. [CrossRef] [PubMed]
89. Ye, Y.; Wang, W.; Yearsley, K.; Gao, J.-X.; Barsky, S.H. ERa suppresses slug expression directly by translational repression. Biochem. J. 2008, 416, 179–187. [CrossRef] [PubMed]
90. Ye, Y.; Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J.-X.; Shetuni, B.; Barsky, S.H. ER signalling through slug regulates E-cadherin and EMT. Oncogene 2010, 29, 1451–1462. [CrossRef] [PubMed]
91. Fujita, N.; Jaye, D.L.; Kajita, M.; Gelgerman, C.; Moreno, C.S.; Wade, P.A. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113, 207–219. [CrossRef]
92. Wang, M.; Zhao, F.; Li, S.; Chang, A.K.; Jia, Z.; Chen, Y.; Xu, F.; Pan, H.; Wu, H. AIB1 cooperates with ERa to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation. PLoS ONE 2013, 8, e65556. [CrossRef] [PubMed]
93. Chimge, N.-O.; Baniwal, S.K.; Little, G.H.; Chen, Y.; Kahn, M.; Tripathy, D.; Borok, Z.; Frenkel, B. Regulation of breast cancer metastasis by Runx2 and estrogen signalling: The role of SNAI2. Breast Cancer Res. 2011, 13, R127. [CrossRef] [PubMed]
94. Lu, T.; Lin, W.-J.; Izumi, K.; Wang, X.; Xu, D.; Fang, L.-Y.; Li, L.; Jiang, Q.; Jin, J.; Chang, C. Targeting Androgen Receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol. Endocrinol. 2012, 26, 1707–1715.
95. Wu, K.; Gore, C.; Yang, L.; Fazli, L.; Gleave, M.; Pong, R.-C.; Xiao, G.; Zhang, L.; Yun, E.-J.; Tseng, S.-F., et al. Slug, a unique Androgen-regulated transcription factor, coordinates Androgen Receptor to facilitate castration resistance in prostate cancer. Mol. Endocrinol. 2012, 26, 1496–1507. [CrossRef] [PubMed]
96. Chang, C.; Lee, S.O.; Yeh, S.; Chang, T.M. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2014, 33, 3225–3234. [CrossRef] [PubMed]
97. Stender, J.D.; Kim, K.; Charn, T.H.; Komm, B.; Chang, K.C.N.; Kraus, W.L.; Benner, C.; Glass, C.K.; Katzenellenbogen, B.S. Genome-wide analysis of Estrogen Receptor a DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 2010, 30, 3943–3955. [CrossRef] [PubMed]
98. Hill, L.; Browne, G.; Tulchinsky, E. ZEB/miR-200 feedback loop: At the crossroads of signal transduction in cancer. Int. J. Cancer 2013, 132, 745–754. [CrossRef] [PubMed]
99. Hurteau, G.J.; Carlson, J.A.; Spivack, S.D.; Brock, G.J. Overexpression of the MicroRNA has-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67, 7972–7976. [CrossRef] [PubMed]
100. Feng, X.; Wang, Z.; Filmore, R.; Xi, Y. miR-200, a new star miRNA in human cancer. Cancer Lett. 2014, 344, 166–173. [CrossRef] [PubMed]
101. Hilmarsdottir, B.; Briem, E.; Bergthorsson, J.T.; Magnusson, M.K.; Gudjonsson, T. Functional role of the microRNA-200 family in breast morphogenesis and neoplasia. Genes 2014, 5, 804–820. [CrossRef] [PubMed]
102. Bracken, C.P.; Li, X.; Wright, J.A.; Lawrence, D.M.; Pillman, K.A.; Salmanidis, M.; Anderson, M.A.; Dredge, B.K.; Gregory, P.A.; Tsykin, A., et al. Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J. 2014, 33, 2040–2056. [CrossRef] [PubMed]
103. Brabletz, S.; Brabletz, T. The ZEB/ miR-200 feedback loop- a motor of cellular plasticity in development and cancer? EMBO Rep. 2010, 11, 670–677. [CrossRef] [PubMed]
104. Chamberlain, E.M.; Sanders, M.M. Identification of the novel player dEF1 in estrogen transcriptional cascades. Mol. Cell. Biol. 1999, 19, 3600–3606. [CrossRef] [PubMed]
105. Spoeltra, N.S.; Manning, N.G.; Higashi, Y.; Darling, D.; Singh, M.; Shroyer, K.R.; Broaddus, R.R.; Horwitz, K.B.; Richer, J.K. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006, 66, 3893–3902. [CrossRef] [PubMed]
106. Hurt, E.M.; Saykally, J.N.; Anose, B.M.; Kalli, K.R.; Sanders, M.M. Expression of the ZEB1 (d EF1) transcription factor in human: Additional insights. Mol. Cell. Biochem. 2008, 318, 89–99. [CrossRef] [PubMed]
107. Tuomarila, M.; Luostari, K.; Soini, Y.; Kataja, V.; Kosma, V.-M.; Mannermaa, A. Overexpression of micro-RNA-200c predicts poor outcome in patients with PR-negative breast cancer. PLoS ONE 2014, 9, e109508. [CrossRef] [PubMed]
108. Manavalan, T.T.; Teng, Y.; Litchfield, L.M.; Muluhngwi, P.; Al-Rayyan, N.; Klinge, C.M. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE 2013, 8, e62334. [CrossRef] [PubMed]
109. Richer, J.K.; Jacobsen, B.M.; Manning, N.G.; Abel, M.G.; Wolf, D.M.; Horwitz, K.B. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 2002, 277, 5209–5218. [CrossRef] [PubMed]
110. Anose, B.M.; Sanders, M.M. Androgen receptor regulates transcription of the ZEB1 transcription factor. Int. J. Endocrinol. 2011, 2011, 903-918. [CrossRef] [PubMed]
111. Graham, T.R.; Yacoub, R.; Taliaferro-Smith, L.; Osunkoya, A.O.; Odero-Marah, V.A.; Liu, T.; Kimbro, K.S.; Sharma, D.; O’Reagan, R.M. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res. Treat. 2010, 123, 139–147. [CrossRef] [PubMed]
112. Kasimir-Bauer, S.; Hoffmann, O.; Wallwiener, D.; Kimmig, R.; Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14, R15. [CrossRef] [PubMed]
113. Van Nes, J.G.; de Kruijf, E.M.; Putter, H.; Faratian, D.; Munro, A.; Campbell, F.; Smit, V.T.H.B.M.; Liefers, G.-J.; Kuppen, P.J.K; van de Velde, C.J.H., et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat. 2012, 133, 49–59. [CrossRef] [PubMed]
114. Tilghman, S.L.; Townley, I.; Zhong, Q.; Carriere, P.P.; Zou, J.; Llopis, S.D.; Preyan, L.C.; Williams, C.C.; Skripnikova, E.; Bratton, M.R., et al. Proteomic signatures of acquired letrozole resistance in breast cancer: Suppresssed estrogen signalling and increased cell motility and invasiveness. Mol. Cell. Proteom. 2013, 12, 2440–2455. [CrossRef] [PubMed]
115. Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; van der Groep, P.; Artemov, D.; Kowalski, J.; Carraway, H.; van Diest, P., et al. Twist contributes to hormone resistance in breast cancer by down-regulating estrogen receptor alpha. Oncogene 2012, 31, 3223–3234. [CrossRef] [PubMed]
116. Fu, J.; Zhang, L.; He, T.; Xiao, X.; Liu, X; Wang, L.; Yang, L.; Yang, M.; Zhang, T.; Chen, R., et al. TWIST represses Estrogen Receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells. Int. J. Biol. Sci. 2012, 8, 522–532. [CrossRef] [PubMed]
117. Lapidus, R.G.; Ferguson, A.T.; Ottaviano, Y.L.; Parl, F.F.; Smith, H.S.; Weitzman, S.A.; Baylin, S.B.; Issa, J.P.; Davidson, N.E. Methylation of estrogen receptor gene 5’ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 1996, 2, 805–810. [PubMed]
118. Cubillo, E.; Diaz-Lopez, A.; Cuevas, E.P.; Moreno-Bueno, G.; Peinado, H.; Montes, A.; Santos, V.; Portillo, F.; Cano, A. E47 and Id1 interplay in epithelial-mesenchymal transition. PLoS ONE 2013, 8, e59948. [CrossRef] [PubMed]
119. Perk, J.; Gil-Bazo, I.; Chin, Y.; de Candia, P.; Chen, J.J.; Zhao, Y.; Chao, S.; Cheong, W.; Ke, Y.; Al-Ahmadie, H., et al. Reassessement of Id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res. 2006, 66, 10870–10877. [CrossRef] [PubMed]
120. Mani, S.A.; Yang, J.; Brooks, M.; Schwaninger, G.; Zhou, A.; Miura, N.; Kutok, J.L.; Hartwell, K.; Richardson, A.L.; Weinberg, R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2007, 104, 10069–10074. [CrossRef] [PubMed]
121. Bard, J.B.L.; Lam, M.S.; Aitken, S. A bioinformatics approach for identifying candidate transcriptional regulators of Mesenchyme-to-Epithelium Transitions in mouse embryos. Dev. Dyn. 2008, 237, 2748–2754. [CrossRef] [PubMed]
122. Hader, C.; Marlier, A.; Cantley, L. Mesenchymal-epithelial transition in epithelial response to injury: The role of Foxc2. Oncogene 2010, 29, 1031–1040. [CrossRef] [PubMed]
123. Grønning, L.M.; Cederberg, A.; Miura, N.; Evenbäck, S.; Taskén, K. Insulin and TNF induce expression of the Forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol. Endocrinol. 2002, 16, 873–883. [PubMed]
124. Golden, D.; Cantley, L.G. Casen kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm. Oncogene 2015, 34, 4702–4712. [CrossRef] [PubMed]
125. Hollier, B.G.; Tinnirello, A.A.; Werden, S.J.; Evans, K.W.; Taube, J.H.; Roy Sarkar, T.; Sphyris, N.; Shariati, M.; Kumar, S.V.; Battula, V.L., et al. FOXC2 expression links Epithelial-Mesenchymal Transition and stem cell properties in breast cancer. Cancer Res. 2012, 73, 1981–1992. [CrossRef] [PubMed]
126. Hartwell, K.A.; Muir, B.; Reinhardt, F.; Carpenter, A.E.; Sgroi, D.C.; Weinberg, R.A. The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc. Natl. Acad. Sci. USA 2006, 103, 18969–18974. [CrossRef] [PubMed]
127. Watabe, T.; Kim, S.; Candia, A.; Rothbächer, U.; Hashimoto, C.; Inoue, K.; Cho, K.W.Y. Molecular mechanisms of Spemann’s organizer formation: Conserved growth factor synergy between Xenopus and mouse. Genes Dev. 1995, 9, 3038–3050. [CrossRef] [PubMed]
128. Xue, T.-C.; Ge, N.-L.; Zhang, L.; Cui, J.-F.; Chen, R.-X.; You, Y.; Ye, S.-L.; Ren, Z.-G. Goosecoid promotes the metastasis of hepatocellular carcinoma by modulating the epithelial-mesenchymal transition. PLoS ONE 2014, 9, e109695. [CrossRef] [PubMed]
129. Ell, B.; Kang, Y. Transcriptional control of cancer metastasis. Trends Cell Biol. 2013, 23, 603–611. [CrossRef] [PubMed]
130. Gross, M.K.; Moran-Rivard, L.; Velasquez, T.; Nakatsu, M.N.; Jagla, K.; Goulding, M. Lbx1 is required for muscle precursor migration along a lateral pathway into the limb. Development 2000, 127, 413–424. [PubMed]
131. Yu, M.; Smolen, G.A.; Zhang, J.; Wittner, B.; Schott, B.J.; Brachtel, E.; Ramaswamy, S.; Maheswaran, S.; Haber, D.A. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009, 23, 1737–1742. [CrossRef] [PubMed]
132. Jozwik, K.M.; Carroll, J.S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 2012, 12, 381–385. [CrossRef] [PubMed]
133. Carroll, J.S.; Liu, X.S.; Brodsky, A.S.; Li, W.; Meyer, C.A.; Szary, A.J.; Eeckhoute, J.; Shao, W.; Hestermann, E.V.; Geistlinger, T.R., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122, 33–43. [CrossRef] [PubMed]
134. Robinson, J.L.; Carroll, J.S. FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front. Endocrinol. 2012, 3, 68. [CrossRef] [PubMed]
135. Robinson, J.L.L.; MacArthur, S.; Ross-Innes, C.S.; Tilley, W.D.; Neal, D.E.; Mills, I.G.; Carroll, J.S. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011, 30, 3019–3027. [CrossRef] [PubMed]
136. Guiu, S.; Charon-Barra, C.; Vernerey, D.; Fumoleau, P.; Campone, M.; Spielmann, M.; Roché, H.; Mesleard, C.; Arnould, L.; Lemonnier, J., et al. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: Ancillary study from PACS08 trial. Future Oncol. 2015, 11, 2283–2297. [CrossRef] [PubMed]
137. Liu, Y.N.; Lee, W.W.; Wang, C.Y.; Chao, T.H.; Chen, Y.; Chen, J.H. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24, 8277–8290. [CrossRef] [PubMed]
138. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715. [CrossRef] [PubMed]
139. Preca, B.-T.; Bajdak, K.; Mock, K.; Sundararajan, V.; Pfannstiel, J.; Maurer, J.; Wellner, U.; Hopt, U.T.; Brummer, T.; Brabletz, S., et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int. J. Cancer 2015, 137, 2566–2577. [CrossRef] [PubMed]
140. Xiao, D.; He, J. Epithelial mesenchymal transition and lung cancer. J. Thorac. Dis. 2010, 2, 154–159. [PubMed]
141. Huang, J.; Li, H.; Ren, G. Epithelial-mesenchymal transition and drug resistance in breast cancer. Int. J. Oncol. 2015, 47, 840–848. [CrossRef] [PubMed]
142. Fischer, K.R.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.C.; Choi, H.; El Rayes, T.; Ryu, S.; Troeger, J., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015, 527, 472–476. [CrossRef] [PubMed]